CS5001 + gemcitabine + oxaliplatin

**CS5001 + gemcitabine + oxaliplatin** is a combination regimen under clinical investigation for the treatment of advanced solid tumors and certain lymphomas. CS5001 is an antibody-drug conjugate (ADC) composed of a fully human monoclonal antibody targeting ROR1 (Receptor tyrosine kinase-like orphan receptor 1), conjugated via a tumor-selective cleavable β-glucuronide linker to a prodrug form of pyrrolobenzodiazepine (PBD) dimer, a potent DNA cross-linking cytotoxin. Gemcitabine is a nucleoside analog that acts as an antimetabolite, inhibiting DNA synthesis; oxaliplatin is a platinum-based chemotherapeutic that causes DNA cross-linking and cell death. The combination leverages complementary mechanisms: targeted delivery and DNA damage (CS5001), inhibition of DNA synthesis (gemcitabine), and further DNA cross-linking (oxaliplatin) to increase anticancer efficacy. CS5001 is being developed by CStone Pharmaceuticals, LegoChem Biosciences, and ABL Bio for use in ROR1-expressing hematologic and solid malignancies[1][2][3][4].